# Detecting and assessing specification failures before submission
> A specification failure discovered after an IND submission exposes two separate assessment needs: evaluating the scientific and patient-safety significance of the result, and understanding why earlier review controls failed. Teams must investigate technical causes, determine the impact on clinical material and submission content, and establish whether correction, additional data, or regulatory communication is required. Multiple signatures alone do not ensure an effective substantive review.
- Status: Current. Last verified 2026-10-15.
- Applies to: Qualitative synthesis of 17 public practitioner discussions, October 2026. Not facts about AskDona, verified audit findings or prevalence statistics.
- Canonical: https://askdona.com/ai/assessment-challenge-13-specification-failures-before-submission.md
13
**Category: CONTROL | Subcategory: Document**
Assessment area: Quality / Submission Assessment
A specification failure discovered after an IND submission exposes two separate assessment needs: evaluating the scientific and patient-safety significance of the result, and understanding why earlier review controls failed. Teams must investigate technical causes, determine the impact on clinical material and submission content, and establish whether correction, additional data, or regulatory communication is required. Multiple signatures alone do not ensure an effective substantive review.
A reported IND case concerned a test result discovered to be outside an acceptance criterion only after the associated information had passed multiple internal reviews and been included in a submission. Such a discovery prompts two separate lines of assessment: understanding the technical meaning of the failing result and establishing why established review controls did not detect it earlier.
The significance of the result depends on the product, the attribute measured, the nature of the specification, and the possible effect on safety, quality, or clinical use. Depending on the investigation, additional testing, technical justification, revised manufacturing activity, or submission updates may be required. None of those pathways follows automatically from the word 'failure.' At the same time, a repeated or systemic gap in document review may need an independent corrective response.
The core challenge is to integrate analytical investigation, product impact assessment, quality oversight, and regulatory communication without assuming either that every specification failure is catastrophic or that it can be dismissed through paperwork.
---
## AskDona Assessment — Detecting and Assessing Specification Failures Before Submission
**Topic ID:** 13
**Category:** CONTROL | **Subcategory:** Document
**Assessment area:** Quality / Submission Assessment
**Challenge status:** Current · verified 2026-10-15
**Application focus:** Specification/acceptance-criteria verification, OOS investigation completeness, clinical-material impact, submission consistency, substantive Quality Unit review, and accountable regulatory follow-up.
> **Source integrity and interpretation.** Section 1 reproduces the original challenge verbatim. The quoted passages in Section 2 and in the findings below are **verbatim wording from the supplied FDA Warning Letter–derived analytical text**, **not direct quotations from FDA Warning Letters**. **[Outdated — marked 2026-10-16]** Its interpretations and selected case descriptions are not independently verified here. **Updated (16 Oct 2026):** all 28 linked FDA pages were opened and each Section 2 insight checked; the result is given as a “Fact check” note. The FDA URLs at the end are supplied for follow-up and copy/paste. The source analysis includes drug manufacturing, laboratory and postapproval examples; their applicability to a particular IND-stage material, test and development phase must be determined by qualified specialists. The AskDona workflows described below are proposals using documented capabilities, not claims that the platform independently decides OOS validity, patient safety, GMP compliance, regulatory reportability, or IND amendment requirements.
### 1. Original Challenge — Verbatim
#### 1.1 Title and classification
**Detecting and assessing specification failures before submission**
**Current · verified 2026-10-15 · 13**
**Category: CONTROL | Subcategory: Document**
**Assessment area: Quality / Submission Assessment**
#### 1.2 Original summary
> A specification failure discovered after an IND submission exposes two separate assessment needs: evaluating the scientific and patient-safety significance of the result, and understanding why earlier review controls failed. Teams must investigate technical causes, determine the impact on clinical material and submission content, and establish whether correction, additional data, or regulatory communication is required. Multiple signatures alone do not ensure an effective substantive review.
#### 1.3 Full original discussion
> A reported IND case concerned a test result discovered to be outside an acceptance criterion only after the associated information had passed multiple internal reviews and been included in a submission. Such a discovery prompts two separate lines of assessment: understanding the technical meaning of the failing result and establishing why established review controls did not detect it earlier.
>
> The significance of the result depends on the product, the attribute measured, the nature of the specification, and the possible effect on safety, quality, or clinical use. Depending on the investigation, additional testing, technical justification, revised manufacturing activity, or submission updates may be required. None of those pathways follows automatically from the word ‘failure.’ At the same time, a repeated or systemic gap in document review may need an independent corrective response.
>
> The core challenge is to integrate analytical investigation, product impact assessment, quality oversight, and regulatory communication without assuming either that every specification failure is catastrophic or that it can be dismissed through paperwork.
#### 1.4 Core problem statement
The organization must prove **both** that the out-of-criterion result received an appropriate, scientifically grounded disposition **and** that the upstream detection/review controls were examined and corrected where necessary. A completed approval workflow is not evidence by itself that the underlying acceptance criteria, raw results and submission statements were actually reconciled.
### 2. FDA Warning Letter–Derived Insights — Verbatim Supplied Analysis
The following selections preserve the wording of the analytical source and its original reference numbers. The analysis also refers to FDA inspection guidance, which should not be described as a Warning Letter.
#### 2.1 OOS investigation must address laboratory evidence
> When a test result is found to be out-of-specification (OOS), the investigation must follow a structured, scientifically sound path rather than automatically dismissing the result or assuming a simple administrative error [3, 20].
> The first step must be a formal Phase I laboratory investigation to determine if the OOS result was caused by an obvious error within the laboratory [20].
**Fact check (16 Oct 2026, against the linked FDA pages):** **First sentence partly supported; second not supported as worded.** Surmasis [3] says it is inappropriate to use an outlier test to invalidate results and asks for a clear, scientifically sound root cause; the 1993 QC laboratories guide [20] says products cannot be “tested into compliance” and that an investigation is more than a retest. “Administrative error” is the analysis's phrase. “Phase I” does **not** appear in the 1993 guide [20], which predates FDA's 2006 OOS guidance; recent letters such as [4], [13], [26] and [28] use “Phase 1/I”.
#### 2.2 Inconclusive laboratory root cause cannot justify closure
> A possible laboratory error is never sufficient to close an OOS investigation [4, 13, 26, 28]. If the laboratory investigation is inconclusive—meaning a clear, documented laboratory root cause cannot be established—the firm must immediately initiate a thorough manufacturing investigation to evaluate potential process or equipment errors [3, 20, 26].
**Fact check (16 Oct 2026, against the linked FDA pages):** **Partly supported; absolutes added.** [4], [13], [26] and [28] say almost word for word that “a possible laboratory error is insufficient to close an investigation at Phase 1”; “never” and dropping “at Phase 1” broaden it. Surmasis [3] and Persōn & Covey [26] say a thorough investigation of potential manufacturing causes “must be performed” when laboratory error is not conclusively shown; “immediately” appears in none of the sources ([26] says “timely” and “promptly”), and [20] does not set out this escalation rule.
#### 2.3 Retesting, outliers and averaging cannot replace a rationale
> Invalidating any initial OOS result requires conclusive, documented evidence [2, 8, 18, 20]. Speculative hypotheses—such as assuming sample glassware was dirty, HPLC columns lacked efficiency, or an analyst incorrectly rinsed a vial—without concrete analytical proof are insufficient to invalidate a test failure [5, 18].
**Fact check (16 Oct 2026, against the linked FDA pages):** **Partly supported; examples attributed.** “Conclusive” evidence of laboratory error comes from Claris [18] and from remediation requests in Clarins [8] and HNC [2]; the 1993 guide [20] says a result can be invalidated “when laboratory error has been documented”. Dirty sample glassware is from Zhuhai United [5]; “poor column efficiency” and incorrectly rinsed HPLC vials are both from Claris [18], where FDA found a conclusion “based on an unproven hypothesis” insufficient.
#### 2.4 Signatures do not equal substantive source-data review
> When a failing result passes through multiple internal reviews unnoticed, it exposes a fundamental gap in Quality Unit (QU) oversight. Relying solely on "multiple signatures" does not ensure a substantive review [23].
> A common reason review controls fail is that the Quality Unit limits its review to finalized summary sheets rather than evaluating complete raw data records [23].
**Fact check (16 Oct 2026, against the linked FDA pages):** **First paragraph not supported; second partly.** Nortec Quimica [23] (API) describes **no failing result that passed multiple reviews**, and “multiple signatures”, “multiple reviews” and “unnoticed” do not appear; its signature reference concerns worksheet forms lacking a unique number or signature. FDA found that the QU “did not review the complete record of the raw data generated during each test”, but “finalized summary sheets” is the analysis's wording. The nearest support for a review gap is Intas 2023 [13]: unreported raw data “could not be detected during the QA review process.”
#### 2.5 Data integrity and computerized records
> Additionally, firms must establish robust, computerized controls over laboratory spreadsheets (like Excel) and Laboratory Information Management Systems (LIMS) to prevent unauthorized access, data modification, or the overwriting of original OOS results [2, 23, 25, 27].
**Fact check (16 Oct 2026, against the linked FDA pages):** **Partly supported.** Sichuan Friendly [27] cites a non-validated, unprotected Excel spreadsheet. HNC [2] found original OOS data overwritten and managers able to delete and overwrite results, without mentioning Excel or LIMS. Nortec [23] found analysts could delete and overwrite data (LIMS appears only in a remediation request). Seatex [25] **does not fit**: it concerns OOS results not being recorded, with no computerized-systems content.
#### 2.6 Submission specifications must be scientifically justified
> Companies cannot rely on the mere approval of a process in an application if that process does not consistently work in practice [15]. Even if a wide specification range (such as for particle size or hardness) is established in a filing, those ranges must be verified and tightened if process validation reveals they adversely affect final drug performance [15].
> If a firm determines that an established specification is inappropriate, any subsequent modification to the specification or test methods must be backed by rigorous scientific justification, validated, and reported to regulatory bodies through the proper supplement pathways [6, 12, 24].
**Applicability note:** The last sentence reflects the supplied source's broad regulatory analysis. It does **not** mean that an IND uses the same postapproval supplement pathway; the appropriate IND safety reporting, information amendment, protocol amendment, or other communication, if any, requires a case-specific regulatory determination.
**Fact check (16 Oct 2026, against the linked FDA pages):** **Partly supported.** The 1994 OSD inspection guide [15] says companies “cannot hide behind the approval of processes listed in an application when these processes do not work”, and that wide particle-size or surface-area ranges should be verified in process validation; tightening appears only in one example, and hardness and supplements are not mentioned. On specification changes: Aurobindo [24] found method and control changes “not reported to FDA through a supplement” (21 CFR 314.70); ABS Corporation [12] (an **animal-drug** letter from CVM) changed an assay limit during validation without justification; Intas 2026 [6] concerns OOS assays and method validation, not reporting specification changes. Both guides ([15] January 1994, [20] July 1993) are non-binding reference material for FDA investigators.
### 3. Findings and AskDona Assessment Mapping
Each finding contains (A) original FDA-derived insight, (B) regulatory/operational finding, (C) AskDona perspective, (D) proposed solution, (E) expected benefit, and (F) capability boundary.
#### Finding 01 — An acceptance-criterion failure escaped multiple document reviews
**A. Original FDA-derived insight**
> When a failing result passes through multiple internal reviews unnoticed, it exposes a fundamental gap in Quality Unit (QU) oversight. Relying solely on "multiple signatures" does not ensure a substantive review [23].
**B. Finding.** Approved forms, signatures and submission-ready summaries may conceal a mismatch between numerical test results, approved specifications and the reported compliance conclusion. The failure is both a product-quality question and an independent review-control question.
**C. AskDona Assessment perspective.** Define distinct assessment criteria for **result-versus-limit consistency** and **evidence of substantive reviewer checks**. A completed signature field alone must never be treated as proof of the latter.
**D. Proposed solution.** Import expert-authored Excel checklist items covering the current specification/version, result and units, pass/fail statement, original raw-data location, reviewer checklist and submission section. Use RAG to retrieve the relevant SOP, CoA, laboratory summary, controlled specification, review form and submission draft. Return a preliminary label, reason, quotations and source file. Route mismatches and missing source records to QA for direct verification. Numerical comparators should be independently implemented and validated rather than left to free-form LLM arithmetic.
**E. Expected benefit.** Earlier identification of conflicting statements and greater visibility into whether a review genuinely addressed the applicable criterion.
**F. Capability boundary.** RAG-backed criterion evaluation and Excel export are documented current functions. Fully automated numeric extraction from instrument records, direct LIMS validation, reviewer-workflow enforcement and system-of-record approvals require separately scoped implementation.
#### Finding 02 — OOS disposition lacks a complete Phase I laboratory review
**A. Original FDA-derived insight**
> The first step must be a formal Phase I laboratory investigation to determine if the OOS result was caused by an obvious error within the laboratory [20].
**B. Finding.** A hypothesis of analytical error is not a completed investigation; omitted checks of methods, calculations, instrumentation or raw data leave the disposition unsupported.
**C. AskDona Assessment perspective.** Evaluate **presence, completeness and traceability** of the organization-defined laboratory investigation evidence, not whether the AI believes a result is valid or invalid.
**D. Proposed solution.** Configure criteria for prompt event reporting, analyst/supervisor review, method/version, system suitability, instrument calibration, sample preparation, calculation review, raw-data review and documented conclusion. AskDona identifies which controlled documents support each criterion, which are inconsistent and which cannot be found.
**E. Expected benefit.** More consistent initial completeness checks and fewer investigations advanced to closure with unresolved evidence gaps.
**F. Capability boundary.** AskDona does not conduct laboratory science, inspect an instrument directly, or autonomously prove assignable cause.
#### Finding 03 — Inconclusive lab findings do not trigger manufacturing impact review
**A. Original FDA-derived insight**
> A possible laboratory error is never sufficient to close an OOS investigation [4, 13, 26, 28]. If the laboratory investigation is inconclusive—meaning a clear, documented laboratory root cause cannot be established—the firm must immediately initiate a thorough manufacturing investigation to evaluate potential process or equipment errors [3, 20, 26].
**B. Finding.** The investigation may stop at an inconclusive analytical explanation without considering batch records, material variability, equipment, deviations or process trends.
**C. AskDona Assessment perspective.** Separate **laboratory-cause evidence** from **manufacturing-cause evidence**, then evaluate the documented escalation decision as its own criterion.
**D. Proposed solution.** Assess whether the approved procedure's Phase II trigger is met, whether a manufacturing investigation and relevant batch/material/equipment evidence are documented, and whether the conclusion accounts for conflicting facts. Use metadata filtering to restrict the evidence set to the correct material, lot, product, method and development period.
**E. Expected benefit.** Reduced risk of premature investigation closure and clearer handoff between analytical, manufacturing and Quality Unit teams.
**F. Capability boundary.** Trigger logic must be expert-defined and configured. Automatic opening of a manufacturing investigation in QMS is a prospective integration, not an established current capability.
#### Finding 04 — Retests or statistical arguments obscure the original failure
**A. Original FDA-derived insight**
> Invalidating any initial OOS result requires conclusive, documented evidence [2, 8, 18, 20]. Speculative hypotheses—such as assuming sample glassware was dirty, HPLC columns lacked efficiency, or an analyst incorrectly rinsed a vial—without concrete analytical proof are insufficient to invalidate a test failure [5, 18].
**B. Finding.** A narrative can appear scientific while the original failed value, authorized retest protocol, raw results or invalidation rationale are missing.
**C. AskDona Assessment perspective.** Treat each disposition claim as an **evidence-demanding assertion**: what was observed, why was it invalidated (if applicable), and what controlled procedure permits the action?
**D. Proposed solution.** Compare initial result, repeats, documented retest authorization, deviation/investigation text and relevant SOP against expert-defined checks. Flag missing original results, unsupported assignable-cause statements and unexplained averaging/outlier references for specialist review. Preserve the conflicting quoted passages in the assessment report.
**E. Expected benefit.** Reduced risk of paperwork-based closure and better reviewability of challenged analytical conclusions.
**F. Capability boundary.** Scientific validity of statistical treatment must be determined by qualified analytical/statistical specialists; AskDona should not invent rules or adjudicate data invalidation.
#### Finding 05 — Submitted statements are not reconciled with controlled data
**A. Original FDA-derived insight**
> A common reason review controls fail is that the Quality Unit limits its review to finalized summary sheets rather than evaluating complete raw data records [23].
**B. Finding.** A submission may repeat a transcribed pass statement that does not reflect source analytical results, approved limits, or the correct method/specification revision.
**C. AskDona Assessment perspective.** Build a **claim-to-evidence review** for each material specification and associated submission statement, including status and revision metadata.
**D. Proposed solution.** Define a structured reconciliation checklist for attribute, lot, analytical method, specification version, actual reported value, units, conclusion and submission section. Use current document retrieval and source quotations to assemble the package for expert verification. In a future integrated implementation, feed validated structured numerical comparisons into the review rather than relying solely on extracted prose.
**E. Expected benefit.** Better pre-submission detection of unsupported claims and less retrospective reconstruction after an IND is filed.
**F. Capability boundary.** The current assessment engine is not a validated end-to-end submission publishing, laboratory data-integrity, or structured numerical reconciliation system.
#### Finding 06 — Clinical-material impact is assumed rather than evaluated
**A. Original FDA-derived insight**
> Companies cannot rely on the mere approval of a process in an application if that process does not consistently work in practice [15].
**B. Finding.** The existence of an accepted document does not establish that an affected quality attribute has no implications for the actual clinical batch, population, route of administration or study context.
**C. AskDona Assessment perspective.** Assess whether a **documented, product-specific impact rationale** exists, with appropriate scientific inputs and Quality/Regulatory ownership. Keep a technical quality disposition separate from a regulatory notification decision.
**D. Proposed solution.** Configure criteria for affected lots and doses, disposition/hold status, stability or potency implications as applicable, patient exposure, clinical-use context, linked deviation, safety assessment, and designated decision-makers. Assemble source-linked gaps for medical, CMC, Quality and Regulatory review.
**E. Expected benefit.** More complete impact-assessment packages and fewer unsupported assumptions of either catastrophic or negligible consequence.
**F. Capability boundary.** AskDona cannot determine clinical safety, product release, continued dosing, trial interruption, or regulatory reporting obligations autonomously.
#### Finding 07 — Specification or method changes lack change-control and regulatory rationale
**A. Original FDA-derived insight**
> If a firm determines that an established specification is inappropriate, any subsequent modification to the specification or test methods must be backed by rigorous scientific justification, validated, and reported to regulatory bodies through the proper supplement pathways [6, 12, 24].
**B. Finding.** Changing an acceptance range after observing a failure can obscure whether the change is justified by development science or intended to retroactively make an outlying result appear compliant.
**C. AskDona Assessment perspective.** Assess the **provenance and rationale of the limit**, the controlled change record, validation or qualification evidence, and the documented consideration of filing impact.
**D. Proposed solution.** Compare specification revisions, method-change justification, development/biobatch data where relevant, associated change controls, test evidence and filing text. Return gaps and contradictory version references to a designated regulatory reviewer.
**E. Expected benefit.** More defensible specification governance and improved alignment between laboratory practice and IND content.
**F. Capability boundary.** The proper IND communication or amendment route is case-specific and remains the responsibility of regulatory counsel/affairs; postapproval supplement examples should not be mechanically applied to an IND.
#### Finding 08 — A detected mismatch is fixed, but the review-system failure is not
**A. Original FDA-derived insight**
> When a failing result passes through multiple internal reviews unnoticed, it exposes a fundamental gap in Quality Unit (QU) oversight. Relying solely on "multiple signatures" does not ensure a substantive review [23].
**B. Finding.** Correcting one report or submission table does not address a potentially systemic breakdown in review design, training, access to raw data, or verification of specification versions.
**C. AskDona Assessment perspective.** Open a **second, independent assessment track**: evaluate why the initial checks did not detect the inconsistency and whether related documents/events require review.
**D. Proposed solution.** Import checklist criteria for review procedure adequacy, evidence inspected by reviewers, training, analogous attributes/lots/submissions, documented CAPA decision and effectiveness review. Rerun selected criteria when updated records become available, and send findings to the authoritative QMS workflow for approval.
**E. Expected benefit.** Reduces repetition of the same detection failure and keeps system-level remediation distinct from the specific OOS scientific disposition.
**F. Capability boundary.** Periodic manual reruns and cited preliminary assessments are supported; autonomous retrospective screening across all LIMS/QMS/EDMS records and continuous CAPA effectiveness monitoring depend on future integration and validation.
### 4. Proposed Operating Model — Two Parallel Assessment Tracks
| Stage | Track A — Scientific / Product Impact | Track B — Review Control / Process Effectiveness | Responsible decision-maker |
|---|---|---|---|
| 1. Intake | Identify attribute, result, method, specification and affected clinical lot | Identify point of detection and completed review/approval steps | QC and QA |
| 2. Scope | Review raw data and laboratory investigation; expand manufacturing investigation when warranted | Identify applicable SOP, source-data checks and reviewer responsibilities | QC, Manufacturing, QA |
| 3. Evidence assembly | Test records, instruments, batch records, stability, prior results, patient exposure as relevant | Signed reviews, approval checklists, audit trails, training and submission history | Qualified SMEs |
| 4. Preliminary assessment | Criterion-by-criterion sufficiency, contradiction and missing evidence | Criterion-by-criterion detection-control adequacy | AskDona prepares, humans interpret |
| 5. Expert adjudication | Determine analytical validity, product/clinical impact and disposition | Decide review-control remediation, retrospective scope and CAPA necessity | Authorized QA, CMC, clinical and regulatory personnel |
| 6. Regulatory outcome | Decide whether and how to correct or communicate submitted information | Verify future submission review contains effective source-data checks | Regulatory Affairs with accountable Quality leadership |
| 7. Reassessment | Recheck open issues as new evidence is available | Verify implemented process changes and effectiveness | Designated quality system owners |
**Design principle:** A single assessment worksheet can hold both tracks, but **a scientific OOS conclusion and a review-process CAPA conclusion must not be conflated**.
### 5. Example AskDona Assessment Checklist for a Pilot
These are **proposed expert-authored criteria**, not an automatically generated regulatory checklist or a declaration of mandatory requirements for every IND.
| ID | Proposed criterion | Primary evidence | Escalation trigger / uncertain result |
|---|---|---|---|
| SS-01 | The reviewed result is matched to its approved acceptance criterion, method, version, units and sample/lot. | Specification, method, result, CoA | Missing or contradictory identifiers |
| SS-02 | The original failing value remains available and distinguishable from all repeats. | Raw data, LIMS, audit trail | Initial result absent or overwritten |
| SS-03 | The Phase I laboratory review addresses applicable method, calculation, equipment and raw-data checks. | OOS form, laboratory log, calibration | Incomplete scope or only speculative cause |
| SS-04 | The invalidation or retest decision has a documented, permitted and scientifically supported basis. | Investigation, SOP, retest plan | Conclusion without evidence |
| SS-05 | When lab cause is inconclusive, the required manufacturing evaluation is documented or its absence justified. | Batch records, deviation, process records | No documented escalation rationale |
| SS-06 | Affected clinical materials, lots and any patient-exposure implications have been evaluated by qualified personnel. | Material disposition, clinical supply log, safety/CMC review | Product impact absent or unclear |
| SS-07 | Submission assertions can be traced to the actual result and correct specification revision. | IND module, reports, raw result, controlled limits | Filing and source data disagree |
| SS-08 | The submission/review record shows the substantive checks performed, not only approval signatures. | Review checklist, QA record, audit trail | Signatures without documented data review |
| SS-09 | Potential impact on related lots, methods, attributes or filings has been considered. | Trending, batch history, similar reports | No documented scope decision |
| SS-10 | Any specification or method change has documented scientific and change-control rationale. | Change control, studies, SOP revision | Revised limit without justification |
| SS-11 | Regulatory Affairs has assessed whether a communication, amendment, correction or other action is needed. | Regulatory assessment, correspondence log | No owner or documented conclusion |
| SS-12 | The detected review-process failure has a separate corrective-action disposition and accountable reviewer. | Deviation/CAPA, training, effectiveness plan | Individual correction only; systemic question open |
#### Suggested preliminary label scheme
- **Supported:** The supplied controlled evidence addresses the *defined checklist criterion* and contains no identified inconsistency.
- **Gap / Inconsistent:** Required evidence is explicitly missing or source passages contradict one another under the expert-defined rule.
- **Cannot determine:** The relevant record, version, raw data or context is not available in the scoped evidence set, or the question requires specialist adjudication.
- **Not applicable:** An expert-approved rule excludes the criterion for this case; preserve the exclusion rationale.
These are **configurable suggested labels**; they should not be mistaken for a built-in validated OOS decision taxonomy. A missing file in the repository does not prove the record never existed or that a GMP violation occurred.
#### Illustrative assessment output
```text
Criterion: SS-07 — Submitted specification statement matches controlled analytical result
Preliminary result: Cannot determine
Reason: The submission summary states the result conforms, but the source analytical
record and effective approved specification revision were not both available within
the scoped evidence set. The result cannot be reconciled from the supplied records.
Evidence: [Verbatim excerpts from available records, if any]
Sources: [Document filenames / versions]
Required human action: Retrieve authoritative raw data and effective specification,
perform an independent validated numerical check, determine material impact,
and document whether the IND content requires an update or communication.
```
### 6. AskDona Capability Mapping and Boundaries
| Capability / proposition | Evidence-based status | Appropriate implementation claim |
|---|---|---|
| Import assessment items from Excel and export item-level findings | **Documented current Batch Assessment functionality** | Build a repeatable pre-submission review checklist. |
| RAG retrieval across supplied documents; output label, reason, quotation and source file | **Documented current functionality** | Prepare citation-linked preliminary evidence checks for expert review. |
| Pre-questions, metadata-based evidence scoping and item exclusion | **Documented current functionality** | Scope review to the relevant lot/product/method when metadata are correctly maintained. |
| Configurable Cannot determine/insufficient-evidence handling | **Documented configuration approach** | Surface unresolved evidence instead of silently assuming a pass. |
| Repeat assessment and retain/export outcomes | **Documented current workflow** | Recheck selected items when documents change; maintain controlled comparison externally as appropriate. |
| Evaluate technical validity of OOS cause, perform validated numerical checks, choose retests | **Not established as an autonomous capability** | Keep analytical scientists and validated computational checks in control. |
| Live LIMS/eQMS/EDMS integration, automated filing comparison or CAPA workflow actions | **Integration concept; implementation dependent** | Scope and validate partner-specific connectors and permissions before claiming automation. |
| Fully deterministic assessment across all deployments | **Research demonstration under particular pipeline conditions, not a general commercial guarantee** | Validate actual production reproducibility and source fidelity for intended use. |
| Final material disposition, IND amendment/reporting or safety decision | **Human decision only** | Preserve regulatory, scientific and Quality Unit accountability. |
**Additional guardrail:** The supplied research distinguishes reproducibility from correctness. Repeating an unsupported assessment perfectly does not make it scientifically valid. Source quotations should be checked against authoritative records; the current output structure does not itself prove the cited passage supports the final regulatory judgment.
### 7. Suggested Implementation and Pilot Measurement
#### 7.1 Pilot scope
Select one fictionalized or de-identified development-stage OOS/acceptance-criterion mismatch with a known review history. Include a current approved specification and an earlier revision, source test data, summary report, a draft filing excerpt, signatures/review checklists, relevant laboratory/manufacturing investigation records, and at least one deliberately missing or contradictory document. Independent experts should define the expected result before reviewing AskDona outputs.
#### 7.2 Pilot workflow
1. Define intended use, product/development context, scope and decision owners.
2. Have QC, QA, CMC and Regulatory Affairs author and approve the 12 pilot criteria and escalation policy.
3. Load controlled, appropriately permissioned documents into the designated RAG database; tag product, lot, method, document version and effective date.
4. Run the checklist on a small sample; inspect citations against originals, especially numbers and units.
5. Independently perform validated source-data/specification comparisons; do not accept LLM-generated mathematics without verification.
6. Compare AskDona preliminary outcomes with blinded SME adjudication and record false assurance, missed conflicts and missing-evidence detection.
7. Repeat after introducing corrected specification, additional evidence or a revised submission statement; document changes and human decisions in the authoritative quality system.
#### 7.3 KPI framework — targets must be established in the pilot
| KPI | Measurement | Intended improvement |
|---|---|---|
| Pre-submission mismatch detection | Confirmed result/limit/filing conflicts detected ÷ seeded conflicts | Fewer escaped inconsistencies |
| Evidence traceability | Checks with verifiable correct-version sources ÷ all checks | More reviewable decisions |
| False assurance rate | Unsupported or contradictory cases incorrectly marked supported ÷ relevant cases | Lower false confidence |
| Investigation completeness | Required laboratory/manufacturing evidence elements found or flagged | Earlier escalation of gaps |
| Review-control effectiveness | Approvals with documented substantive checks ÷ reviewed packages | Less reliance on signature count |
| Expert review effort | Median review time per case compared with manual baseline | Less mechanical document searching |
| Regulatory decision readiness | Cases with documented qualified owner, decision and supporting basis | Faster accountable follow-up |
| Version discrimination | Cases correctly distinguishing current versus superseded specification | Fewer obsolete-limit comparisons |
**No efficacy percentage is claimed for this use case.** A security-assessment PoC reported in the supplied internal material does not establish pharmaceutical IND/OOS accuracy or time savings.
### 8. Expected Organizational Effects
With appropriate controls and validation, AskDona Assessment may help teams:
- **Find contradictions sooner:** compare controlled specifications, reported values, summary conclusions and filing narratives before submission.
- **Standardize investigative completeness:** make missing laboratory/manufacturing evidence and unproven root causes visible under approved rules.
- **Distinguish two root problems:** keep scientific disposition of the test failure separate from analysis of why the review process missed it.
- **Make uncertainty explicit:** escalate missing or conflicting evidence rather than manufacture a confident pass/fail conclusion.
- **Reduce reconstruction burden:** produce item-level rationales with cited documents that qualified reviewers can inspect.
- **Focus expertise where it matters:** shift time away from document hunting toward scientific, Quality Unit and regulatory judgment.
These are *prospective benefits*, conditional on source quality, intended-use validation, human oversight and effective integration with the organization's controlled records.
### 9. FDA Source URLs — Markdown Links for Copy/Paste
The links below correspond to the numbered references in the **supplied analytical material**. **[Outdated — marked 2026-10-16]** They are provided as direct, copyable Markdown hyperlinks, **not as independent substantiation that every analysis statement precisely reflects the original FDA document**. **Updated (16 Oct 2026):** all 28 linked FDA pages were opened and each Section 2 insight checked; the result is given as a “Fact check” note. Firm names, letter numbers and dates match. All are drug, API or OTC letters except [12] (animal drugs, CVM) and the two inspection guides [15] and [20]. **None of the 28 sources concerns an IND** or a failing result that passed multiple reviews into a submission; the nearest is Lupin [10], where an OOS content-uniformity result on an exhibit batch was invalidated as a “probable laboratory error” and FDA found that insufficient. [1], [7], [9]–[11], [14], [16], [17], [19], [21] and [22] are listed but not cited in the text. Entries include inspection guidance as well as Warning Letters.
1. [DuPont Nutrition USA Inc. — 627211 — 12/02/2022](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dupont-nutrition-usa-inc-627211-12022022)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dupont-nutrition-usa-inc-627211-12022022`
2. [HNC Products Inc. — 607359 — 09/10/2020](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hnc-products-inc-607359-09102020)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hnc-products-inc-607359-09102020`
3. [Surmasis Pharmaceutical — 553686 — 11/06/2018](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/surmasis-pharmaceutical-553686-11062018)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/surmasis-pharmaceutical-553686-11062018`
4. [ALI Pharmaceutical Manufacturing, LLC — 645781 — 03/30/2023](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ali-pharmaceutical-manufacturing-llc-645781-03302023)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ali-pharmaceutical-manufacturing-llc-645781-03302023`
5. [Zhuhai United Laboratories Co. Ltd. — 542230 — 06/27/2018](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhuhai-united-laboratories-co-ltd-542230-06272018)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhuhai-united-laboratories-co-ltd-542230-06272018`
6. [Intas Pharmaceuticals Limited — 721151 — 03/30/2026](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-721151-03302026)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-721151-03302026`
7. [Pharmathen International S.A. — 723680 — 05/27/2026](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmathen-international-sa-723680-05272026)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmathen-international-sa-723680-05272026`
8. [Laboratoires Clarins — 568157 — 04/23/2019](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratoires-clarins-568157-04232019)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratoires-clarins-568157-04232019`
9. [Glenmark Pharmaceuticals Limited — 637314 — 11/22/2022](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glenmark-pharmaceuticals-limited-637314-11222022)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glenmark-pharmaceuticals-limited-637314-11222022`
10. [Lupin Limited — 535014 — 11/06/2017](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lupin-limited-535014-11062017)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lupin-limited-535014-11062017`
11. [Eco Lips, Inc. — 631629 — 09/20/2022](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eco-lips-inc-631629-09202022)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eco-lips-inc-631629-09202022`
12. [ABS Corporation — 732115 — 07/23/2026](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/abs-corporation-732115-07232026)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/abs-corporation-732115-07232026`
13. [Intas Pharmaceuticals Limited — 652067 — 07/28/2023](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-652067-07282023)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-652067-07282023`
14. [Signa SA de CV — 605219 — 07/14/2020](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/signa-sa-de-cv-605219-07142020)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/signa-sa-de-cv-605219-07142020`
15. [Oral Solid Dosage Forms Pre/Post Approval Issues (1/94)](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/oral-solid-dosage-forms-prepost-approval-issues-194)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/oral-solid-dosage-forms-prepost-approval-issues-194`
16. [Health Pharma USA LLC — 588155 — 12/18/2019](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/health-pharma-usa-llc-588155-12182019)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/health-pharma-usa-llc-588155-12182019`
17. [Laboratorios Quantium LLC — 569146 — 02/25/2019](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorios-quantium-llc-569146-02252019)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorios-quantium-llc-569146-02252019`
18. [Claris Injectables Limited — 543187 — 07/05/2018](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/claris-injectables-limited-543187-07052018)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/claris-injectables-limited-543187-07052018`
19. [FICOSOTA LTD — 594591 — 02/28/2020](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ficosota-ltd-594591-02282020)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ficosota-ltd-594591-02282020`
20. [Pharmaceutical Quality Control Labs (7/93)](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/pharmaceutical-quality-control-labs-793)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/pharmaceutical-quality-control-labs-793`
21. [Haw Par Healthcare Limited — 578581 — 08/19/2019](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/haw-par-healthcare-limited-578581-08192019)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/haw-par-healthcare-limited-578581-08192019`
22. [BR SAS — 542617 — 06/08/2018](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/br-sas-542617-06082018)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/br-sas-542617-06082018`
23. [Nortec Quimica SA — 639894 — 12/08/2022](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nortec-quimica-sa-639894-12082022)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nortec-quimica-sa-639894-12082022`
24. [Aurobindo Pharma Limited — 577033 — 06/20/2019](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aurobindo-pharma-limited-577033-06202019)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aurobindo-pharma-limited-577033-06202019`
25. [Seatex, LLC — 672951 — 04/01/2024](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/seatex-llc-672951-04012024)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/seatex-llc-672951-04012024`
26. [Persōn & Covey, Inc. — 711191 — 09/23/2025](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/person-covey-inc-711191-09232025)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/person-covey-inc-711191-09232025`
27. [Sichuan Friendly Pharmaceutical Co., Ltd. — 546990 — 06/22/2018](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sichuan-friendly-pharmaceutical-co-ltd-546990-06222018)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sichuan-friendly-pharmaceutical-co-ltd-546990-06222018`
28. [Cdymax India Pharma Private Limited — 715022 — 11/13/2025](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cdymax-india-pharma-private-limited-715022-11132025)
`https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cdymax-india-pharma-private-limited-715022-11132025`
---
**Positioning statement:** *AskDona Assessment supports two defensible, evidence-based review questions: Is the specification-failure investigation supported by appropriate product-specific evidence, and did the submission review control actually verify what was approved? It prepares source-linked preliminary assessments so that qualified scientists, Quality Unit personnel and regulatory professionals can reach and document the final decisions.*